Hero banner

Empagliflozin in the Treatment of Chronic Heart Failure

Heart Failure (HF) affects almost 60 million people worldwide (1) – Let’s take action now!

This is an informative and resourceful hub that will help to support your clinical practice, and your knowledge of the role of SGLT2 Inhibitor Empagliflozin in the treatment of chronic heart failure, by:

  • Providing a library of materials, many of which you can download
  • Giving access to the latest guideline update from ESC 20232
  • Detailing the EMPEROR-Preserved trial outcomes3
  • Offering evidence-based information of the benefits of Empagliflozin in HF4

This resource hub is supported by the Boehringer Ingelheim and Lilly Alliance.

1. Groenewegen A, Rutten FH, Mosterd A, W. Hoes A, Epidemiology of heart failure. European Journal of Heart Failure 2020; 22, 1342-1356. doi: 10.1002/ejhf.1858

2. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2023 Aug 25]. Eur Heart J. 2023;ehad195. doi:10.1093/eurheartj/ehad195 

3. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR- Preserved results and the publication's Supplementary Appendix.) 

4.JARDIANCE® [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; [December 2023].

Latest Content

What's New for Chronic Heart Failure?

The 2023 ESC Congress introduced a focused update of the 2021 heart failure guidelines, with new recommendations. SGLT2 inhibitors, such as JARDIANCE®, have now received a class I level A recommendation for the treatment of chronic heart failure across the LVEF spectrum; HFrEF, HFmrEF, and HFpEF.1


Listen to Prof Theresa McDonagh, the co-chair of both the 2021 ESC HF guidelines2 and the 2023 ESC Focused Update1, explaining the evidence behind this new recommendation.

 

1. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2023 Aug 25]. Eur Heart J. 2023;ehad195. doi:10.1093/eurheartj/ehad195 

2. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2021;00:1-128. doi:10.1093/eurheartj/ehab368

 

About Heart Failure

3D Animation Healthy Heart
Normal Heart Function
3D Animation Healthy Heart

Watch the true-to-life 3D heart animation developed in collaboration with renowned cardiologists and experience the beating heart in action.

3D Animation Heart Failure with Reduced Ejection Fraction
HFrEF
3D Animation Heart Failure with Reduced Ejection Fraction

Look into the beating heart and explore the structural and functional limitations of a heart with reduced ejection fraction in a true-to-life 3D animation.

3D Animation Heart Failure with Preserved Ejection Fraction
HFpEF
3D Animation Heart Failure with Preserved Ejection Fraction

Find out more about the structural and functional impact of heart failure with preserved ejection fraction in a true-to-life 3D animation.

High Risks for Patients With Heart Failure
High Risks for Patients With Heart Failure
High Risks for Patients With Heart Failure

Did you know 75% of patients with HF die within five years of diagnosis – regardless of LVEF?

Explore this short two-minute video for evidence-based information.

Evidence for SGLT2i in Heart Failure

Infographic Clinical Benefits
Benefits Across the LVEF Spectrum
Infographic Clinical Benefits

Did you know that Empagliflozin is the first HF drug to significantly reduce the risk of CV death or first HHF across the LVEF spectrum1-2?

Explore the clinical benefits of Empagliflozin across the LVEF spectrum at a glance, in this informative infographic, that is available to download for use in your clinical workshops. Click ‘see more’.

EMPEROR-Preserved Trial Summary
EMPEROR-Preserved
EMPEROR-Preserved Trial Summary

Watch this, concise, short video, for a summary of the EMPEROR-Preserved trial design and the result from this significant trial.

EMPEROR-Reduced Trial Summary
EMPEROR-Reduced
EMPEROR-Reduced Trial Summary

Prof Javed Butler, summarises the results of the EMPEROR-Reduced trial in this concise short video, with illustrated slides throughout.

EMPULSE Trial Summary
EMPULSE
EMPULSE Trial Summary

Prof Ponikowski summarises the results of the EMPULSE trial and explains the win-ratio analysis. Learn more about in-hospital initiation and the early benefits of Empagliflozin in this short video with animations.

EMPEROR-Preserved
EMPEROR-Preserved
Educational Slide Module

This educational slide module compliments the Trial Summary and the Trial Presentation, by providing an overview of the EMPEROR-Preserved trial design and summarises the endpoint, and the safety and the tolerability results. Available for you to download, click ‘see more’.

EMPEROR-Reduced
EMPEROR-Reduced
Educational Slide Module

This educational slide module provides an overview of the EMPEROR- Reduced trial design and summarises both the endpoint results and the safety and tolerability results. Available for you to download, click ‘see more’.

EMPEROR-Preserved Trial Presentation
EMPEROR-Preserved
EMPEROR-Preserved Trial Presentation

This video provides you with an opportunity to watch the full trial presentation, presented by Prof Stefan Anker, with detailed slides throughout, providing an informative 20-minute presentation.

Benefits of Jardiance in HF Treatment

JARDIANCE®: Proven Benefits Across the LVEF Spectrum

Proven protection

Reduced risk of CV death and HHF across the LVEF spectrum 1,2

Protected the kidneys by slowing the decline of renal function †1,2

Additionally, provided early and sustained symptom relief 4,5


Proven safety and tolerability profile across multiple trials3

 

Simple dosing: oral, once daily, no titration ‡3

†The rate of decline in eGFR was a prespecified secondary outcome of the EMPEROR-Reduced and EMPEROR-Preserved trials.

‡When JARDIANCE is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. 

 

Download references:

Download

Patient Cases and Patient Resources

Patient Newly Diagnosed With HFpEF
Patient Case
Newly Diagnosed HFpEF Patient

Meet Kristina, a 71-year-old retired schoolteacher. After physical examination and H2FPEF score she is diagnosed with HFpEF. You initiate the suitable guideline recommended treatment(s) and adjust medication over the 2-months follow-up period.

Download this interactive patient case as a self-learning experience or to incorporate into presentations and workshops.

Patient With HFpEF and Comorbidities of CKD and T2D
Patient Case
Patient With HFpEF and Comorbidities of CKD and T2D

Meet Irene, a 73-year-old grandmother diagnosed with HFpEF two years ago. She experiences intermittent chest pain and progressive shortness of breath on exertion. Irene has been referred to for further investigation and based on examinations her medication is adjusted and recommended changes to lifestyle.

Download this interactive patient case as a self-learning experience or to incorporate into presentations and workshops.

Patient Hospitalised With HFrEF
Patient Case
Patient Hospitalised With HFrEF

Meet Peter, a 63-year-old male. Peter has been admitted with acute decompensated heart failure. He has suitable examinations and multiple analyses to optimise his treatment.

Download this interactive patient case as a self-learning experience or to incorporate into presentations and workshops.

Safety

Safety Information

Proven Safety and Tolerability Profile Across Multiple Trials1

Very common AEs:
  • Volume depletion: The frequency was increased in patients aged 75 years and older (JARDIANCE 10mg 2.3% vs placebo 2.1%) compared to overall (JARDIANCE® 10 mg 0.6% vs placebo 0.3%) The most frequent adverse reaction of the pooled EMPEROR-Reduced and EMPEROR-Preserved studies was volume depletion (JARDIANCE® 10 mg 11.4% vs placebo 9.7%).
  • Hypoglycaemia (when used with a sulphonylurea or insulin): A lower dose of the sulphonylurea or insulin may be considered to reduce the risk.
Common AEs:
  • Urinary tract infections, serum lipids increased (total cholesterol), genital infections, increased urination, thirst, constipation, pruritus (generalised), and rash.
Uncommon AEs:
  • Angioedema, blood creatinine increased/glomerular filtration rate decreased, diabetic ketoacidosis, dysuria, haematocrit increased, and urticaria.
Rare AEs:
  • Necrotising fasciitis of the perineum (Fournier’s gangrene).

Download the Jardiance SmPC via the download button below.

Reporting Adverse Events Side Effects 

1.JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany; Boehringer Ingelheim International GmbH

Download